Brainstorm Cell Therapeutics, Inc. (BCLI) 14-day ATR is 0.09: This Stock is Set to Soar Above its Peers

Witnessing the stock’s movement on the chart, on Wednesday, Brainstorm Cell Therapeutics, Inc. (NASDAQ: BCLI) had a quiet start as it plunged -4.13% to $0.69, before settling in for the price of $0.72 at the close. Taking a more long-term approach, BCLI posted a 52-week range of $0.13-$3.43.

Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.

Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!

Get the FREE Report with all the details here.


In the past 5-years timespan, the Healthcare sector firm’s annual sales growth was 0.00%. Meanwhile, its Annual Earning per share during the time was 10.57%. This publicly-traded company’s shares outstanding now amounts to $60.49 million, simultaneously with a float of $40.23 million. The organization now has a market capitalization sitting at $33.76 million. At the time of writing, stock’s 50-day Moving Average stood at $0.4043, while the 200-day Moving Average is $0.7794.

Brainstorm Cell Therapeutics, Inc. (BCLI) Ownership Facts and Figures

Nothing is more important than checking the behaviour of major investors towards the stock of the Biotechnology industry. Brainstorm Cell Therapeutics, Inc.’s current insider ownership accounts for 17.86%, in contrast to 8.09% institutional ownership. According to the most recent insider trade that took place on Sep 01 ’23, this organization’s Co-Chief Executive Officer bought 11,500 shares at the rate of 1.77, making the entire transaction reach 20,402 in total value, affecting insider ownership by 181,500.

Brainstorm Cell Therapeutics, Inc. (BCLI) Earnings and Revenue Records

As on 6/29/2023, Multinational firm has announced its last quarter scores, in which it reported -$0.27 earnings per share (EPS) for the period falling under the consensus outlook (set at -$0.15) by -$0.12. Wall Street market experts anticipate that the next fiscal year will bring earnings of 0 per share during the current fiscal year.

Brainstorm Cell Therapeutics, Inc. (NASDAQ: BCLI) Trading Performance Indicators

Let’s observe the current performance indicators for Brainstorm Cell Therapeutics, Inc. (BCLI). It’s Quick Ratio in the last reported quarter now stands at 0.24. The Stock has managed to achieve an average true range (ATR) of 0.09.

In the same vein, BCLI’s Diluted EPS (Earnings per Share) trailing twelve months is recorded -0.41.

Technical Analysis of Brainstorm Cell Therapeutics, Inc. (BCLI)

Going through the that latest performance of [Brainstorm Cell Therapeutics, Inc., BCLI]. Its last 5-days volume of 0.99 million indicated improvement to the volume of 0.96 million it revealed a year ago. During the previous 9 days, stock’s Stochastic %D was recorded 82.00% While, its Average True Range was 0.1008.

Raw Stochastic average of Brainstorm Cell Therapeutics, Inc. (BCLI) in the period of the previous 100 days is set at 83.90%, which indicates a major rise in contrast to 78.01% during the last 2-weeks. If we go through the volatility metrics of the stock, In the past 14-days, Company’s historic volatility was 202.55% that was higher than 165.88% volatility it exhibited in the past 100-days period.